Carotid stenting with proximal cerebral protection in symptomatic low-grade vulnerable recurrent carotid stenosis. (June 2018)

• Record Type: Journal Article
• Authors: de Haro, Joaquin; Rodriguez-Padilla, Javier; Bleda, Silvia; Cañibano, Cristina; Michel, Ignacio; Acin, Francisco
• Is Part Of: Therapeutic advances in chronic disease. Volume 9:Number 6(2018)
• Page Start: 125
• Page End: 133
• Publication Date: 2018-06
• Subjects: carotid stenting -- low-grade stenosis -- proximal embolic protection device -- recurrent neurological symptoms -- vulnerable plaque; Chronic diseases -- Periodicals; Chronic diseases -- Treatment -- Periodicals; Chronic Disease -- Periodicals; Chronic Disease -- therapy -- Periodicals; 616.044
• DOI: 10.1177/2040622318765727
• Languages: English
• ISSNs: 2040-6223

Abstract

Background: Although the management of carotid disease is well established for symptomatic lesions ⩾70%, carotid revascularization for symptomatic low-grade (⩽50%) stenosis is not actually supported by data from randomized clinical trials. Such patients may occasionally have recurrent neurological symptoms despite optimal medical treatment owing to vulnerable plaques. In such cases, carotid artery stenting (CAS) may represent an option for treatment but this has not been tested in clinical trials. This study analyzed early and long-term outcomes of CAS performed in patients with low-grade symptomatic recurrent carotid stenosis. Methods: From a prospective registry of 322 carotid revascularization in symptomatic patients, 21 consecutive patients with low-grade symptomatic recurrent carotid stenosis who underwent CAS with proximal cerebral protection device Mo.Ma, after ruling out any other source of cerebral embolization, were involved in the study. All patients had suggestive evidence of unstable plaque or plaque ulceration. Results: Procedural technical success rate was 100%. No 30-day stroke or death occurred, and no patients had recurrent neurological events related to the revascularized hemisphere during follow up. No 30-day local complications were reported. No late carotid occlusions were detected. There was one late death, and no stroke-related deaths. Survival rates were 100% at 1 year and 96% at 3 years. Conclusions: This study shows that CAS is a well-tolerated, effective and durable treatment for patients with recurrent symptomatic low-grade carotid stenosis associated with a vulnerable plaque. Patients had excellent protection against further ischemic events and survived long enough.